BELLUS Health Inc.
BELLUS Health Inc. (BLU) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blu · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BELLUS Health Inc. (BLU) measures how much investors pay for each dollar of the company's trailing earnings. BLU's current PE ratio of N/A is calculated by dividing its stock price of $14.74 by its TTM earnings per share of -$0.66.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BELLUS Health Inc.You BLU | $1.9B | N/A | — | -$0.66 |
 Ambrx Biopharma Inc. AMAM | $1.8B | N/A | — | -$2.02 |
 Astrana Health, Inc. ASTH | $1.9B | 54.15x | — | $0.46 |
 Calliditas Therapeutics AB (publ) CALT | $2.1B | N/A | — | -$17.37 |
 CinCor Pharma, Inc. CINC | $1.3B | N/A | — | -$1.42 |
 CTI BioPharma Corp. CTIC | $1.2B | N/A | — | -$0.79 |
 DICE Therapeutics, Inc. DICE | $2.3B | N/A | — | -$2.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.66 | — | |
2021-12-31 FY2021 | — | $-0.90 | — | |
2020-12-31 FY2020 | — | $-0.54 | — | |
2019-12-31 FY2019 | — | $-0.49 | — | |
2018-12-31 FY2018 | — | $-0.18 | — | |
2017-12-31 FY2017 | — | $-0.08 | — | |
2016-12-31 FY2016 | — | $-0.10 | — | |
2015-12-31 FY2015 | 334.31x | $0.01 | — | |
2014-12-31 FY2014 | — | $-0.13 | — | |
2013-12-31 FY2013 | — | $-0.06 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BELLUS Health Inc. (BLU) measures how much investors pay for each dollar of the company's trailing earnings. BLU's current PE ratio of N/A is calculated by dividing its stock price of $14.74 by its TTM earnings per share of -$0.66.
Frequently asked questions
BLU pe ratio · 6 questionsBLU's current PE ratio is N/A as of 2026-06-09, based on a stock price of $14.74 and TTM EPS of -$0.66. Data sourced from Financial Modeling Prep via BLU's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BELLUS Health Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09